论文部分内容阅读
目的:评价头孢哌酮-舒巴坦用于治疗老年患者下呼吸道感染的临床疗效及其安全性。方法:选取下呼吸道感染的老年患者100例,根据分组原则将其分为A组与B组,其中A组患者给予头孢哌酮-舒巴坦治疗,B组给予头孢他啶治疗,并对比A、B两组患者经治疗后细菌清除率及总有效率等指标。结果:经治疗后对各种细菌分离及清除数量比较,其结果显示治疗后A组清除率(92.31%)高于B组(57.69%)(P<0.05);A组总有效率(100%)显著高于B组(88.0%)(P<0.05)。结论:临床使用头孢哌酮-舒巴坦治疗老年患者下呼吸道感染的疗效高且不易产生耐药性。
Objective: To evaluate the clinical efficacy and safety of cefoperazone-sulbactam in the treatment of lower respiratory tract infection in elderly patients. Methods: A total of 100 elderly patients with lower respiratory tract infection were divided into group A and group B according to the principle of grouping. Group A received cefoperazone-sulbactam, group B received ceftazidime, and compared with group A and group B Two groups of patients after treatment of bacterial clearance and total effective rate and other indicators. Results: After treatment, the numbers of bacteria isolated and cleared were compared. The results showed that the clearance rate of group A was higher (92.31%) than that of group B (57.69%) after treatment (P <0.05) ) Was significantly higher than that in group B (88.0%) (P <0.05). Conclusion: The clinical use of cefoperazone-sulbactam in elderly patients with lower respiratory tract infection is highly effective and not easy to produce drug resistance.